Name | 3-[(6S,9S,12S,15S,18S,21S,23aS,28aR,34S,37S,40S,42aS,47aS)-37-(4-Aminobutyl)-40-(3-amino-3-oxopropyl)-6-[(2S)-2-butanyl]-34-(4-hydroxybenzyl)-15-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-12-methyl-21-octyl-5,8,11,14,17,20,23,28,33,36,39,42,47-tridecaoxotetratetracontahydro-1H,5H,28H-tetrapyrrolo[1,2-a:1',2'-d:1'',2''-p:1''',2'''-s][1,4,7,10,13,16,19,22,25,28,31,34,37]tridecaazacyclononatriacontin-18-yl]propanoic acid |
---|---|
Synonyms |
1H,5H,28H-Tetrapyrrolo[1,2-a:1',2'-d:1'',2''-p:1''',2'''-s][1,4,7,10,13,16,19,22,25,28,31,34,37]tridecaazacyclononatriacontine-18-propanoic acid, 37-(4-aminobutyl)-40-(3-amino-3-oxopropyl)tetratetracontahydro-15-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-34-[(4-hydroxyphenyl)methyl]-12-methyl-6-[(1S)-1-methylpropyl]-21-octyl-5,8,11,14,17,20,23,28,33,36,39,42,47-tridecaoxo-, (6S,9S,12S,15S,18S,21S,23aS,28aR,34S,37S,40S,42aS,47aS)-
3-[(6S,9S,12S,15S,18S,21S,23aS,28aR,34S,37S,40S,42aS,47aS)-37-(4-Aminobutyl)-40-(3-amino-3-oxopropyl)-6-[(2S)-2-butanyl]-34-(4-hydroxybenzyl)-15-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-12-methyl-21-octyl-5,8,11,14,17,20,23,28,33,36,39,42,47-tridecaoxotetratetracontahydro-1H,5H,28H-tetrapyrrolo[1,2-a:1',2'-d:1'',2''-p:1''',2'''-s][1,4,7,10,13,16,19,22,25,28,31,34,37]tridecaazacyclononatriacontin-18-yl]propanoic acid |
Description | Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE)[1][2]. |
---|---|
Related Catalog | |
In Vivo | Lonodelestat (POL6014) significantly and efficiently reduced the inflammatory processes of ALI in HNE treated mice[1]. Lonodelestat (POL6014, 0.1, 0.5, 2 and 10 mg/kg, intranasally administered) dose-dependently and significantly reduces the number of macrophages, epithelial cells, neutrophils and lymphocytes recovered in BAL. The maximum inhibition was reached at 2 mg/kg in reducing neutrophils by 65% (p<0.001), epithelial cells by 68% (p<0.001), macrophages by 33% (p<0.001) and lymphocytes by 77% (p<0.001)[1]. Animal Model: Ten-week-old male C57BL/6j mice[1]. Dosage: 0.05, 0.2, 0.5 and 5 mg/kg. Administration: Administered intranasally (i.n.) 15 minutes before HNE (30 UI, i.n.). Result: Reduced the inflammatory processes of ALI in HNE treated mice. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 1750.2±65.0 °C at 760 mmHg |
Molecular Formula | C71H111N15O19 |
Molecular Weight | 1478.73 |
Flash Point | 1012.3±34.3 °C |
Exact Mass | 1477.818115 |
LogP | -6.74 |
Vapour Pressure | 0.0±0.3 mmHg at 25°C |
Index of Refraction | 1.619 |